Treatment-Continuity of ADHD Compared Using Immediate-Release and Extended-Release MPH
The continuity of methylphenidate (MPH) therapy for ADHD in young Medicaid beneficiaries (ages 6 to 17 years) treated with immediate-release (IR) or extended-release (ER) MPH formulations was compared in an analysis of statewide California Medicaid claims (2000-2003) conducted at Columbia University...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pediatric Neurology Briefs Publishers
2005-07-01
|
| Series: | Pediatric Neurology Briefs |
| Subjects: | |
| Online Access: | https://www.pediatricneurologybriefs.com/articles/1264 |
| Summary: | The continuity of methylphenidate (MPH) therapy for ADHD in young Medicaid beneficiaries (ages 6 to 17 years) treated with immediate-release (IR) or extended-release (ER) MPH formulations was compared in an analysis of statewide California Medicaid claims (2000-2003) conducted at Columbia University, New York; University of Pennsylvania, Philadelphia; and McNeil Pharmaceuticals, Fort Washington, PA. |
|---|---|
| ISSN: | 1043-3155 2166-6482 |